Trust and Transparency in Medical Device Regulation

Kramer DB, Kesselheim AS - BMJ

  • Regulation and Clinical Evidence

Summary:

The authors discuss the FDA’s decision to end its controversial “alternative summary reporting” program for medical device adverse events, which had allowed manufacturers to report safety problems outside public view, arguing that all adverse event reports should be publicly accessible to maintain trust in device regulation.

VIEW SOURCE

Recent Work from PORTAL

Talk bubble graphics representing commentary and opinion.

How Congress Can Fix Expert Advisory Committees

Daval CJR, Kesselheim AS - STAT

  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.

International Regulatory Status and Reimbursement Recommendations of Haematological Malignancy Drugs Withdrawn from the FDA Accelerated Approval Pathway

Mulsant SS, Kesselheim AS, Naci H - Journal of Cancer Policy

  • Price, Value, and Access
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.

Politics and the Patient Encounter, in Dire Times

Avorn J - MedPage Today

  • Regulation and Clinical Evidence